On Friday, Baird downgraded shares of DexCom (NASDAQ:DXCM), a medical device company specializing in glucose monitoring systems, from Outperform to Neutral. The firm also slashed the price target for DexCom's stock to $80 from the previous target of $161.
The decision comes in the wake of DexCom's second-quarter performance, which did not meet expectations, and a significant reduction in the company's guidance for 2024. Baird expressed challenges in fully comprehending the reasons behind the disappointing quarterly results and the lowered future guidance.
The firm acknowledged that while DexCom might rectify many of its current issues in the upcoming quarters, it is concerned about the apparent market share gains by Abbott Laboratories (NYSE:ABT) in the U.S. Durable Medical Equipment (DME) channel, which is a major revenue source for DexCom. Additionally, there is a concern about potential share gains by Abbott in the Automated Insulin Delivery (AID) market.
Automated Insulin Delivery users constitute approximately 33% of DexCom's global installed base. The uncertainty in this segment influenced Baird's decision to downgrade the company's stock. DexCom's challenges in the AID market, coupled with competitive pressures, have introduced new variables that investors are now considering in their assessments of the company's stock performance.
In other recent news, DexCom, a medical device company, reported a 15.3% year-over-year increase in second-quarter earnings, reaching $1,004 million. However, this figure fell short of the projected $1,049 million, leading to several analyst firms adjusting their outlooks.
Piper Sandler reduced its price target from $150 to $90, RBC Capital from $165 to $145, UBS from $163 to $95, and Canaccord Genuity from $145 to $89. Despite the downgrades, all firms maintained positive ratings on the stock, citing potential for future growth.
DexCom's revenue shortfall was attributed to disruptions in the sales force, a decrease in durable medical equipment market share, and changes in rebate pricing within the pharmacy channel. In response to these challenges, DexCom revised its full-year revenue guidance to 11% to 13% organic growth, with revenue expectations between $4.00 billion and $4.05 billion.
Despite these issues, DexCom initiated a share repurchase program of up to $750 million and plans to launch its Stelo product to enhance its competitive position. Analysts from Piper Sandler, RBC Capital, UBS, and Canaccord Genuity remain optimistic about DexCom's long-term prospects, expecting the company to overcome its second-quarter performance issues and maintain strong growth rates.
InvestingPro Insights
Amid the recent downgrade by Baird, DexCom (NASDAQ:DXCM) shows resilience in certain financial metrics that might interest investors looking for a more comprehensive picture. With a market capitalization of $43.22 billion, the company is trading at a P/E ratio of 66.02, which reflects a high earnings multiple but also indicates investor confidence in future earnings growth. The PEG ratio, which adjusts the P/E ratio for expected earnings growth, stands at a modest 0.58, suggesting that DexCom's stock could be undervalued relative to its earnings growth potential.
Furthermore, DexCom's revenue growth over the last twelve months, as of Q1 2024, has been substantial at 25.78%, with a gross profit margin of 62.82% indicating strong profitability at the core operational level. This could signal underlying strength despite the competitive pressures and market challenges noted by Baird. Additionally, two InvestingPro Tips highlight that the company's management has been actively buying back shares and that DexCom is expected to be profitable this year. Such activities often reflect management's belief in the company's value and future prospects.
For investors seeking in-depth analysis, there are 14 additional InvestingPro Tips available for DexCom, which can be accessed through the InvestingPro platform. These tips could provide valuable insights into the company's financial health and market positioning. Interested readers might consider using the coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription to gain comprehensive investment insights.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.